CEO
CNOOC LimitedCEO
CEO
Delisted
CEO was delisted on the 8th of March, 2021.
Financial journalist opinion
Neutral
PRNewsWire
2 months ago
CNOOC Limited Subsidiary Completed the Transaction with INEOS Energy
HONG KONG , April 2, 2025 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces that its wholly owned subsidiary, CNOOC International Limited, has completed closing of the Stock Purchase Agreement with INEOS Energy. — End — Notes to Editors: More information about the Company is available at http://www.cnoocltd.com.
Neutral
Business Wire
4 months ago
Aptemiz Launches with Dynamic Leadership Team to Transform Mission-Driven Services
LOS ANGELES--(BUSINESS WIRE)--Aptemiz, a hybrid SaaS and professional services company, today announced its official launch, setting a new standard for cost allocation, indirect cost recovery, compliance, and operational efficiency solutions tailored for government entities, nonprofits, and mission-driven organizations. “At Aptemiz, we are redefining how mission-driven organizations achieve fiscal and operational excellence,” said Art Elizarov, CEO. “With this incredible leadership team, we're.
Neutral
Business Wire
8 months ago
Morphotonics Appoints Hugo da Silva as New CEO to Lead Company Into Next Phase of Growth
VELDHOVEN, Netherlands--(BUSINESS WIRE)--Morphotonics, a global leader in large-area nanoimprint technology, is proud to announce the appointment of Hugo da Silva as its new Chief Executive Officer (CEO). With over 20 years of experience in advanced materials, manufacturing, and commercialization of high-tech industries, Hugo brings a wealth of knowledge and leadership to guide Morphotonics through its next stage of growth and innovation. Before joining Morphotonics, Hugo served in multiple exe.
Neutral
Business Wire
8 months ago
BenevolentAI Interim Results for the Six Months Ended 30 June 2024
LONDON--(BUSINESS WIRE)--Regulatory News: BenevolentAI ("BenevolentAI" or “the Company" or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2024. Peter Allen, Chair, said: “I was delighted to join the Board as Chair in May, along with the other new Non-Executive Directors, to support the leadership of the Company. BenevolentAI has consistently been a pioneer a.
Charts implemented using Lightweight Charts™